Patents by Inventor Mariano Garcia-Blanco

Mariano Garcia-Blanco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190107542
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Application
    Filed: November 30, 2018
    Publication date: April 11, 2019
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Patent number: 10161939
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: December 25, 2018
    Assignees: Duke University, Janssen Diagnostics, LLC
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Publication number: 20180274033
    Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
    Type: Application
    Filed: March 22, 2018
    Publication date: September 27, 2018
    Applicants: Board of Regents, The University of Texas System, Duke University, Case Western Reserve University, University Of California, Berkeley
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B.S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko
  • Publication number: 20180231560
    Abstract: This disclosure provides compositions and methods for the isolation of cells that express c-MET, and in particular circulating tumor cells that express c-MET. The methods can include contacting a biological sample including a c-MET circulating tumor cell with an unbound complex including a capture binding species linked to a solid phase for a time sufficient to allow the unbound complex to bind an extracellular binding domain of the c-MET protein to form a bound complex, and subsequently isolating the bound complex. Compositions, systems, and kits adapted for use with these methods are also provided.
    Type: Application
    Filed: September 15, 2015
    Publication date: August 16, 2018
    Inventors: Galla Chandra Rao, Mark C. Connelly, Rengasamy BOOMINATHAN, Tian Zhang, Mariano A. Garcia-Blanco, Andrew J. Armstrong
  • Patent number: 9845481
    Abstract: Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: December 19, 2017
    Assignee: Duke University
    Inventors: Matthew S. Marengo, Mariano A. Garcia-Blanco
  • Publication number: 20160281107
    Abstract: Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.
    Type: Application
    Filed: February 29, 2016
    Publication date: September 29, 2016
    Applicant: Duke University
    Inventors: Matthew S. Marengo, Mariano A. Garcia-Blanco
  • Publication number: 20160077097
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Application
    Filed: May 31, 2013
    Publication date: March 17, 2016
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Patent number: 9284575
    Abstract: Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 15, 2016
    Assignee: DUKE UNIVERSITY
    Inventors: Matthew S. Marengo, Mariano A. Garcia-Blanco
  • Patent number: 8883753
    Abstract: Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analog of apoAI. The methods and compositions include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding apoAI, the apoAI Milano variant, or an analog of apoAI. The expression of this apoAI protein results in protection against vascular disorders resulting from plaque build up, i.e., atherosclerosis, strokes and heart attacks.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: November 11, 2014
    Assignee: Virxsys Corporation
    Inventors: Madaiah Puttaraju, Edward Otto, Mariano A. Garcia-Blanco, Gerard J. McGarrity, Gary F. Temple
  • Publication number: 20130254909
    Abstract: Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.
    Type: Application
    Filed: March 4, 2013
    Publication date: September 26, 2013
    Applicant: Duke University
    Inventors: Matthew S. Marengo, Mariano A. Garcia-Blanco
  • Publication number: 20130209493
    Abstract: Provided are methods for detecting circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Application
    Filed: September 24, 2010
    Publication date: August 15, 2013
    Inventors: Mariano Garcia-Blanco, Andrew Armstrong, Daniel George, Sebastian Oltean
  • Patent number: 8158344
    Abstract: The present invention provides, in certain aspects, a method of identifying a subject as having an increased risk of developing multiple sclerosis, comprising detecting in the subject the presence of a nucleotide variant in the interleukin 7 receptor alpha chain gene, whereby the presence of said variant identifies the subject as having an increased risk of developing multiple sclerosis.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: April 17, 2012
    Assignees: Duke University, Vanderbilt University
    Inventors: Jonathan L. Haines, Simon G. Gregory, Silke Schmidt, Margaret A. Pericak-Vance, Mariano Garcia-Blanco
  • Publication number: 20120046347
    Abstract: Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analogue of apoAI. The methods and compositions include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding apoAI, the apoAI Milano variant, or an analogue of apoAI. The expression of this apoAI protein results in protection against vascular disorders resulting from plaque build up, i.e., atherosclerosis, strokes and heart attacks.
    Type: Application
    Filed: June 22, 2011
    Publication date: February 23, 2012
    Applicant: Virxsys Corporation
    Inventors: Madaiah Pattaraju, Edward Otto, Mariano A. Garcia-Blanco, Gerard J. McGarrity, Gary F. Temple
  • Patent number: 8053232
    Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention include those genetically engineered to interact with SERPINA1 target pre-mRNA so as to result in correction of SERPINA1 genetic defects responsible for AAT deficiency. The PTMs of the invention may also comprise sequences that are processed out of the PTM to yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs. Such duplexed siRNAs are designed to reduce the accumulation of toxic AAT protein in liver cells.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: November 8, 2011
    Assignee: VIRxSYS Corporation
    Inventors: Madaiah Puttaraju, Edward Otto, Mariano A. Garcia-Blanco, Gerard J. McGarrity, Gary F. Temple, Lloyd G. Mitchell, Colette Cote, S. Gary Mansfield
  • Publication number: 20110244519
    Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through RNA trans-splicing that target a highly expressed pre-mRNA and contain the coding sequence for antibody polypeptide(s). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with the target precursor messenger RNA molecule (target pre-mRNA) that is abundantly expressed or tumor specific and mediate a trans-splicing reaction resulting in the generation of novel chimeric RNA molecule (chimeric RNA) capable of encoding an antibody polypeptide. The invention provides for the in vivo production of chimeric RNA molecules that encode and result in the production of an antibody polypeptide that is therapeutically effective against, for example, infectious agents, cancer cells, transplantation antigens, rheumatoid arthritis, etc.
    Type: Application
    Filed: January 11, 2011
    Publication date: October 6, 2011
    Applicant: VIRxSYS Corporation
    Inventors: Gerard J. McGarrity, Mariano A. Garcia-Blanco, Madaiah Puttaraju
  • Patent number: 7968334
    Abstract: Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analogue of apoAI. The methods and compositions include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding apoAI, the apoAI Milano variant, or an analogue of apoAI. The expression of this apoAI protein results in protection against vascular disorders resulting from plaque build up, i.e., atherosclerosis, strokes and heart attacks.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: June 28, 2011
    Assignee: VIRxSYS Corporation
    Inventors: Madaiah Puttaraju, Edward Otto, Mariano A. Garcia-Blanco, Gerard J. McGarrity, Gary F. Temple
  • Patent number: 7879321
    Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through RNA trans-splicing that target a highly expressed pre-mRNA and contain the coding sequence for antibody polypeptide(s). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with the target precursor messenger RNA molecule (target pre-mRNA) that is abundantly expressed or tumor specific and mediate a trans-splicing reaction resulting in the generation of novel chimeric RNA molecule (chimeric RNA) capable of encoding an antibody polypeptide. The invention provides for the in vivo production of chimeric RNA molecules that encode and result in the production of an antibody polypeptide that is therapeutically effective against, for example, infectious agents, cancer cells, transplantation antigens, rheumatoid arthritis, etc.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: February 1, 2011
    Assignee: VIRxSYS Corporation
    Inventors: Gerard J. McGarrity, Mariano A. Garcia-Blanco, Madaiah Puttaraju
  • Patent number: 7871795
    Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through RNA trans-splicing that target a highly expressed pre-mRNA and contain the coding sequence of a protein or polypeptide of interest. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with the target precursor messenger RNA molecule (target pre-mRNA) that is abundantly expressed, and mediate a trans-splicing reaction resulting in the generation of novel chimeric RNA molecule (chimeric RNA) capable of encoding a protein or polypeptide of interest. The invention provides for the in vivo production of chimeric RNA molecules that encode and result in the production of a protein or polypeptide of interest.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: January 18, 2011
    Assignee: VIRxSYS Corporation
    Inventors: Gerard J. McGarrity, Mariano A. Garcia-Blanco
  • Publication number: 20090035778
    Abstract: The present invention provides, in certain aspects, a method of identifying a subject as having an increased risk of developing multiple sclerosis, comprising detecting in the subject the presence of a nucleotide variant in the interleukin 7 receptor alpha chain gene, whereby the presence of said variant identifies the subject as having an increased risk of developing multiple sclerosis.
    Type: Application
    Filed: June 26, 2008
    Publication date: February 5, 2009
    Inventors: Jonathan L. Haines, Simon G. Gregory, Silke Schmidt, Margaret A. Pericak-Vance, Mariano Garcia-Blanco
  • Publication number: 20060246422
    Abstract: The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA that is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA that is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism, a toxin that kills the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method.
    Type: Application
    Filed: October 21, 2005
    Publication date: November 2, 2006
    Inventors: Lloyd Mitchell, Mariano Garcia-Blanco, Carl Baker, Madaiah Puttaraju